Abstract
The aim of this study was to investigate the risk of sensorineural hearing loss (SNHL) and the relationship between SNHL and radiation dose to the cochlea and frequency range of hearing loss in patients with head and neck cancer. Pure tone audiometry at 250–12,000 Hz was performed on 29 patients diagnosed with head and neck tumours who were treated with 3-dimensional conformal radiation therapy and followed up for 6 months. Paired t test indicated that the mean air conduction threshold before and after radiotherapy was significantly different (paired t test, p < 0.001). SNHL was observed in 15 patients (51 %) according to CTCAE. SNHL increased to 77 % in patients who had received at least five concurrent cisplatin cycles. There was an increased risk of SNHL for ears receiving a mean dose of 5000 cGy compared to those receiving <5000 cGy. SNHL was more severe at higher frequencies of pure tone audiometry in patients with cisplatin-based chemoradiation. The ototoxicity effect of radiation and cisplatin must be considered in the treatment of head and neck tumours. Increasing the dose of cisplatin, radiation dose of cochlea and follow-up interval time may result in increasing severity and frequency of hearing loss incidences. However, characteristic of radiation-induced SNHL seems to be different from chemoradiation-induced SNHL.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kwong DL, Wei WI, Sham JS, et al. Sensorineural Hearing Loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment. Int J Radiat Oncol Biol Phys. 1996;36(2):281–9.
Chen WC, Liao CT, Tsai HC, et al. Radiation-induced hearing impairment in patients treated for malignant parotid tumour. Ann Otol Rhinol Laryngol. 1999;108:1159–64.
Pan CC, Eisbruch A, Lee JS, et al. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. 2005;61(5):1393–402.
Low WK, Toh ST, Wee J, et al. Sensorineural Hearing Loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol. 2006;24(12):1904–9.
Tsan D-L, Lin C-Y, Kang C-J, et al. The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiat Oncol. 2012;7(1):215.
Oh Y-T, Kim C-H, Choi J-H, et al. Sensory neural hearing loss after concurrent cisplatin and radiation therapy for nasopharyngeal carcinoma. Radiother Oncol. 2004;72(1):79–82.
Hitchcock YJ, Tward JD, Szabo A, et al. Relative contributions of radiation and cisplatin-based chemotherapy to Sensorineural Hearing Loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. 2009;73(3):779–88.
Hua C, Bass JK, Khan R, et al. Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose. Int J Radiat Oncol Biol Phys. 2008;72(3):892–9.
Paulino AC, Lobo M, Teh BS, et al. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys. 2010;78(5):1445–50.
Chan S, Ng W, Kam K, et al. Sensorineural Hearing Loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. Int J Radiat Oncol Biol Phys. 2009;73(5):1335–42.
Grau C, Moller K, Overgaard M, et al. Sensori-neural hearing loss in patients treated with irradiation for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1991;21(3):723–8.
Ho W, Wei W, Kwong D, et al. Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: a prospective study. Head Neck 1999;21(6):547–53.
Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004;26(10):649–55.
Gurney JG, Bass JK. New International Society of Pediatric Oncology Boston ototoxicity grading scale for pediatric oncology: still room for improvement. J Clin Oncol. 2012;30(19):2303–6.
Bhandare N, Jackson A, Eisbruch A, et al. Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys. 2010;76(3):S50–7.
Rybak LP. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otol Head Neck Surg. 2007;15(5):364–9.
Cardinaal RM, de Groot JC, Huizing EH, et al. Cisplatin-induced ototoxicity: morphological evidence of spontaneous outer hair cell recovery in albino guinea pigs? Hear Res. 2000;144(1):147–56.
van Ruijven MW, de Groot JC, Smoorenburg GF. Time sequence of degeneration pattern in the guinea pig cochlea during cisplatin administration: a quantitative histological study. Hear Res. 2004;197(1):44–54.
van Ruijven MW, de Groot JC, Klis SF, et al. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res. 2005;205(1):241–8.
Kim H-J, Lee J-H, Kim S-J, et al. Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity. J Neurosci. 2010;30(11):3933–46.
Akmansu H, Eryilmaz A, Korkmaz H, et al. Ultrastructural and electrophysiologic changes of rat cochlea after irradiation. Laryngoscope. 2004;114(7):1276–80.
Acknowledgments
Authors acknowledge the financial support of the research chancellor of Iran University of Medical Sciences. We are also thankful to the Radiotherapy and Audiometry Departments at Pars General Hospital and Haftome-Tir University Hospital for their collaboration and facilities.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cheraghi, S., Nikoofar, P., Fadavi, P. et al. Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy. Med Oncol 32, 200 (2015). https://doi.org/10.1007/s12032-015-0646-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-015-0646-3